Tryptamine derivatives as 5-ht-1d receptor ligands
CA 2188798 C · Owner: Virginia Commonwealth University · Inventors: Glennon, Richard A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described herein are, tryptamine analogs that display high binding affinity and selectivity, for the 5-HT1D.beta. receptor of, formula (I), wherein R1 is a, group selected from aryl-C1-7alkyl; aryl-C2-7alkoxy; aryl-C2-7alkanoyl, and aryl-C1-7alkanoyloxy wherein, said alkyl, alkoxy, alkanoyl, and alkanoyloxy groups are optionally substituted by a C1-4alkyl, substituent and wherein said aryl group is optionally substituted by, one or more substituent selected from hydroxyl halogen, mercapto, linear or branched C1-4alkyl linear or branched C1-4alkoxy, linear, or branched C1-4alkylthio thiol substituted C1-4alkyl and nitro substituted C1-4alkyl; R and R3 are selected independently from H and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 4, 1995 and granted April 20, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 4, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 4, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.